CJC-1295 + MK-677 Synergy: Dosing & Timing Protocol

CJC-1295 and MK-677 produce profoundly different growth hormone (GH) release patterns that, when properly timed, generate amplification effects neither compound achieves alone. CJC-1295 (DAC) is a GHRH analog that extends endogenous GH pulse duration by binding albumin and resisting enzymatic degradation. Half-life stretches to 6–8 days, creating sustained baseline GH elevation without the sharp peaks that trigger negative feedback. MK-677 (ibutamoren) is a ghrelin mimetic that acts on the GHSR-1a receptor to dramatically increase pulse amplitude. Single doses elevate serum GH by 50–100% within 90 minutes but rapidly downregulate if dosed continuously at high frequency. The synergy emerges because CJC-1295 maintains the signaling foundation while MK-677 delivers the acute surge. But only if you respect the receptor biology that governs both.

Our team has worked with researchers optimizing peptide protocols since 2018, and the gap between effective stacking and wasted compounds comes down to three factors: receptor kinetics, dosing intervals, and the metabolic context each peptide requires to function.

What is the optimal dosing and timing strategy for combining CJC-1295 and MK-677?

CJC-1295 should be dosed at 1–2mg subcutaneously once weekly, administered on a fixed day to maintain consistent baseline GH elevation. MK-677 should be dosed at 12.5–25mg orally in the evening, 4–5 nights per week with 2–3 non-dosing days to prevent receptor desensitization. CJC-1295 establishes the sustained foundation; MK-677 provides the acute amplitude boost. The weekly CJC injection avoids the pulsatile disruption that daily GHRH dosing creates, while intermittent MK-677 preserves ghrelin receptor sensitivity.

The common mistake is treating both compounds as 'daily maintenance' peptides. Stacking them at high frequency every day for weeks. CJC-1295 with DAC doesn't require daily dosing because the drug-albumin complex maintains therapeutic plasma levels across 6–8 days. MK-677 dosed daily at 25mg causes GHSR-1a receptor downregulation within 10–14 days, blunting the GH response by 30–40%. This article covers the receptor mechanisms that dictate stacking protocols, the specific dosing windows that maximize synergy, and the metabolic timing factors that determine whether the compounds amplify or interfere with each other.

Why CJC-1295 and MK-677 Stack: Complementary Mechanisms

CJC-1295 extends growth hormone-releasing hormone (GHRH) signaling by resisting dipeptidyl peptidase-IV (DPP-IV) degradation. The enzyme that normally cleaves native GHRH within 7 minutes of secretion. Adding a drug affinity complex (DAC) allows CJC-1295 to bind serum albumin, creating a half-life of 6–8 days versus the 30-minute half-life of unmodified GHRH. This produces sustained baseline GH elevation without the sharp peaks that trigger somatostatin release (the negative feedback loop that suppresses further GH secretion). Research published by Teichman et al. in the Journal of Clinical Endocrinology & Metabolism demonstrated that single-dose CJC-1295 DAC elevated mean 24-hour GH levels by 200–300% for up to one week, with no rebound suppression. A pattern unachievable with pulsatile GHRH administration.

MK-677 operates through an entirely different pathway: it mimics ghrelin, the 'hunger hormone' that binds growth hormone secretagogue receptor 1a (GHSR-1a) in the hypothalamus and pituitary. Ghrelin signaling triggers acute, high-amplitude GH pulses. Single 25mg doses of MK-677 elevate serum GH by 50–100% within 90 minutes and maintain elevation for 4–6 hours. The amplitude is consistently higher than baseline secretion, but the effect diminishes with continuous daily dosing because GHSR-1a receptors internalize and downregulate when persistently activated. The synergy emerges because CJC-1295 sustains the GHRH-mediated baseline while MK-677 delivers the ghrelin-mediated surge. Two non-overlapping pathways that don't compete for the same receptor.

We've found that stacking protocols fail when researchers treat both compounds as interchangeable 'GH boosters' without accounting for their distinct pharmacokinetics. CJC-1295's week-long half-life means daily injections create cumulative plasma levels that overshoot therapeutic range and trigger compensatory IGF-1 feedback suppression. MK-677's rapid receptor desensitization means daily dosing past two weeks produces diminishing returns. The optimal stack respects both kinetics: weekly CJC-1295 for sustained elevation, intermittent MK-677 for preserved amplitude.

CJC-1295 Dosing Protocol: Weekly Administration

CJC-1295 with DAC should be administered subcutaneously at 1–2mg once weekly, injected on the same day each week to maintain consistent baseline GH elevation. The 6–8 day half-life means therapeutic plasma concentrations persist throughout the dosing interval. Multiple injections per week create unnecessary accumulation without additional GH benefit. Research from Ionescu and Frohman (2006) found that single-dose CJC-1295 (2mg) elevated mean GH and IGF-1 levels for 6–9 days post-injection, with peak effects occurring 48–72 hours after administration and gradual return to baseline by day 8–10.

Subcutaneous injection site rotation (abdomen, thigh, deltoid) prevents localized lipohypertrophy that can impair absorption over time. Inject 1–2 inches away from the navel and rotate quadrants weekly. Our experience working with long-term peptide researchers shows that consistent injection timing. Same day, same approximate time. Produces more stable IGF-1 levels than sporadic dosing, even when total weekly dose is identical.

Dosage titration is unnecessary for most research applications. Starting at 1mg weekly establishes baseline response; if IGF-1 elevation is suboptimal after 3–4 weeks, increase to 1.5mg, then 2mg if needed. Doses above 2mg weekly do not produce proportional GH increases and elevate the risk of peripheral edema and insulin resistance (common with sustained supraphysiological IGF-1). CJC1295 Ipamorelin 5MG 5MG formulations from Real Peptides maintain potency across multiple freeze-thaw cycles when stored at -20°C before reconstitution.

MK-677 Dosing and Timing: Intermittent Protocol

MK-677 should be dosed orally at 12.5–25mg in the evening, 4–5 nights per week with 2–3 non-consecutive off days built into the weekly schedule. Evening administration aligns with natural nocturnal GH secretion patterns. Endogenous GH pulses peak 60–90 minutes after sleep onset, and MK-677's GH release window (90 minutes to 6 hours post-dose) overlaps this period when dosed 1–2 hours before bed. A study by Svensson et al. in the Journal of Clinical Endocrinology & Metabolism found that 25mg MK-677 dosed at night increased mean overnight GH secretion by 97% and morning serum IGF-1 by 55% after 7 days, with no attenuation across the initial treatment period.

The intermittent dosing schedule. Not daily. Is critical to preserving ghrelin receptor sensitivity. GHSR-1a receptors desensitize under continuous agonist exposure: daily 25mg MK-677 for 14+ days reduces peak GH response by 30–40% compared to initial dosing, a phenomenon documented in multiple Phase 2 trials. Taking 2–3 off days per week allows receptor resensitization and prevents the appetite surge and insulin resistance that emerge with sustained high-dose ghrelin mimicry. Our team has consistently observed better sustained GH response with 4–5 days per week at 25mg than with 7 days per week at 12.5mg. The latter produces tolerance faster than the former despite lower total weekly dose.

MK-677 causes transient insulin resistance during the 4–6 hour GH elevation window. Fasting glucose can rise 10–15 mg/dL within 2 hours of dosing. Taking MK-677 on an empty stomach (2+ hours after last meal) and avoiding carbohydrate intake for 1–2 hours post-dose minimizes this effect. MK 677 capsules from Real Peptides are formulated for rapid gastric absorption, with measurable GH elevation detectable within 45–60 minutes of oral administration.

CJC-1295 and MK-677 Synergy Timing: Weekly Stack Structure

Key Takeaways

• CJC-1295 with DAC has a 6–8 day half-life and should be dosed once weekly at 1–2mg subcutaneously to maintain sustained GH baseline without cumulative overshooting.
• MK-677 should be dosed at 12.5–25mg orally in the evening, 4–5 nights per week with 2–3 off days to prevent GHSR-1a receptor desensitization that reduces GH response by 30–40% after 14 days of daily dosing.
• The synergy between CJC-1295 and MK-677 arises because they activate non-overlapping pathways: GHRH signaling (CJC-1295) versus ghrelin receptor activation (MK-677), allowing additive effects without receptor competition.
• Evening MK-677 administration aligns with natural nocturnal GH secretion peaks, producing 90-minute to 6-hour GH elevation windows that overlap endogenous pulsatile release for maximum synergy.
• Optimal weekly stack structure: CJC-1295 (1–2mg) on Monday morning, MK-677 (25mg) on Tuesday, Thursday, Friday, Saturday evenings, with Sunday-Monday as receptor recovery days before the next CJC injection.

What If: CJC-1295 and MK-677 Scenarios

What If I Dose CJC-1295 More Than Once Per Week?

Reduce dosing frequency to once weekly or switch to CJC-1295 No DAC (half-life 30 minutes) if you need more frequent administration. CJC-1295 with DAC accumulates in plasma when dosed more than once weekly. The 6–8 day half-life means the second injection stacks on top of the first, creating sustained supraphysiological IGF-1 levels that trigger compensatory somatostatin release and blunt GH responsiveness. Research by Ionescu and Frohman found that bi-weekly CJC-1295 DAC dosing (2mg every 3–4 days) produced no additional GH benefit versus weekly dosing but increased edema and fasting glucose dysregulation. If your protocol requires more frequent GHRH signaling, use modified GRF 1-29 (CJC-1295 No DAC) at 100–200mcg 2–3 times daily instead. The short half-life prevents accumulation.

What If I Take MK-677 Every Day Without Off Days?

Expect diminished GH response after 10–14 days and consider cycling off entirely for 7–10 days to restore sensitivity. Daily MK-677 at 25mg causes progressive GHSR-1a receptor internalization. By week 3 of continuous dosing, peak GH elevation drops from 80–100% above baseline to 30–40% above baseline, and appetite stimulation intensifies (ghrelin's orexigenic effects persist even as GH effects wane). Taking 2–3 off days per week preserves receptor density and maintains the initial GH response across months of use. If you've already been dosing daily for 3+ weeks, stop MK-677 entirely for 7–10 days, then restart at 4–5 days per week.

What If I Experience Severe Water Retention on CJC-1295?

Reduce CJC-1295 dose to 1mg weekly or discontinue and reassess baseline insulin sensitivity before reintroducing. Peripheral edema and water retention are GH-mediated effects caused by sodium retention in renal tubules and increased capillary permeability. They occur in 10–15% of users at 2mg weekly CJC-1295 and are more common in individuals with pre-existing insulin resistance or metabolic syndrome. Lowering the dose to 1mg weekly reduces IGF-1 elevation by approximately 30%, which often resolves edema within 5–7 days. If edema persists at 1mg, discontinue CJC-1295 and evaluate fasting insulin and HbA1c. Undiagnosed insulin resistance amplifies GH's sodium-retaining effects.

The Clinical Truth About CJC-1295 and MK-677 Synergy

Here's the honest answer: most peptide stack failures aren't dose failures. They're timing failures. CJC-1295 and MK-677 work through entirely different mechanisms and half-lives, but the standard advice ('take both daily') treats them as interchangeable GH boosters. CJC-1295 with DAC lasts a week. Dosing it daily creates cumulative plasma levels that overshoot therapeutic range and trigger IGF-1 feedback suppression. MK-677 desensitizes its own receptor after 10–14 days of continuous dosing. Taking it every night produces tolerance faster than taking it 4–5 nights per week at the same dose. The synergy only exists if you respect the biology: weekly CJC for sustained baseline, intermittent MK-677 for preserved amplitude. Stack them wrong and you're not just wasting compounds. You're actively blunting the response you're trying to amplify.

Metabolic Context and Substrate Availability

Growth hormone's anabolic effects. Protein synthesis, lipolysis, tissue repair. Require substrate availability that most stack protocols ignore. GH elevates circulating free fatty acids and amino acids, but it can't synthesize them from nothing. Stacking CJC-1295 and MK-677 in a prolonged fasted state or severe caloric deficit produces elevated GH and IGF-1 levels without corresponding anabolic outcomes because the metabolic substrates for tissue growth aren't available. Research from Møller et al. in the Journal of Clinical Investigation demonstrated that GH administration during fasting increased lipolysis but suppressed protein synthesis. The body prioritized fuel mobilization over tissue repair.

Optimal metabolic context for CJC-1295 and MK-677 synergy includes adequate daily protein intake (1.6–2.2g per kg bodyweight), caloric intake at or slightly above maintenance, and carbohydrate timing that supports insulin sensitivity. MK-677 causes transient insulin resistance during its 4–6 hour GH elevation window. Dosing it in the evening after a moderate-carbohydrate meal (30–50g carbs) and then fasting overnight allows insulin sensitivity to recover by morning. CJC-1295's sustained GH elevation improves insulin sensitivity when paired with regular resistance training (3+ sessions per week) but worsens it in sedentary contexts.

Our experience working with research teams shows that the metabolic environment determines whether elevated GH translates into measurable body composition changes. Elevated GH in a caloric deficit produces fat loss but minimal lean mass gain. Elevated GH at maintenance calories with adequate protein produces lean mass gain and modest fat loss. Elevated GH in a surplus without training produces minimal body composition change and increased insulin resistance. The peptides create the hormonal environment. Substrate availability and training stimulus determine what happens inside that environment.

If the receptor kinetics concern you, test it before committing to a 12-week protocol. Run CJC-1295 alone for 4 weeks at 1mg weekly, track morning fasted IGF-1 at baseline and week 4, then add MK-677 at 25mg 4 nights per week for another 4 weeks and retest IGF-1. The data will show whether the synergy exists in your specific metabolic context. And whether intermittent MK-677 preserves the response better than daily dosing would.